Literature DB >> 26440132

Phenotypic screening: the future of antibody discovery.

Andrea L Gonzalez-Munoz1, Ralph R Minter1, Steven J Rust2.   

Abstract

Most antibody therapeutics have been isolated from high throughput target-based screening. However, as the number of validated targets diminishes and the target space becomes increasingly competitive, alternative strategies, such as phenotypic screening, are gaining momentum. Here, we review successful phenotypic screens, including those used to isolate antibodies against cancer and infectious agents. We also consider exciting advances in the expression and phenotypic screening of antibody repertoires in single cell autocrine systems. As technologies continue to develop, we believe that antibody phenotypic screening will increase further in popularity and has the potential to provide the next generation of therapeutic antibodies.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26440132     DOI: 10.1016/j.drudis.2015.09.014

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  6 in total

Review 1.  Opportunities and challenges in phenotypic drug discovery: an industry perspective.

Authors:  John G Moffat; Fabien Vincent; Jonathan A Lee; Jörg Eder; Marco Prunotto
Journal:  Nat Rev Drug Discov       Date:  2017-07-07       Impact factor: 84.694

2.  Induction of Genes Implicated in Stress Response and Autophagy by a Novel Quinolin-8-yl-nicotinamide QN523 in Pancreatic Cancer.

Authors:  Yuting Kuang; Na Ye; Armita Kyani; Mats Ljungman; Michelle Paulsen; Haijun Chen; Mingxiang Zhou; Christopher Wild; Haiying Chen; Jia Zhou; Nouri Neamati
Journal:  J Med Chem       Date:  2022-04-19       Impact factor: 8.039

3.  Phenotypic Assessment and the Discovery of Topiramate.

Authors:  Bruce E Maryanoff
Journal:  ACS Med Chem Lett       Date:  2016-06-13       Impact factor: 4.345

4.  Generation of a monoclonal antibody recognizing the CEACAM glycan structure and inhibiting adhesion using cancer tissue-originated spheroid as an antigen.

Authors:  Yumi Sato; Hiroaki Tateno; Jun Adachi; Hiroaki Okuyama; Hiroko Endo; Takeshi Tomonaga; Masahiro Inoue
Journal:  Sci Rep       Date:  2016-04-21       Impact factor: 4.379

5.  A novel inhibitory anti-invasive MAb isolated using phenotypic screening highlights AnxA6 as a functionally relevant target protein in pancreatic cancer.

Authors:  Dermot O'Sullivan; Paul Dowling; Helena Joyce; Edel McAuley; Andrew McCann; Michael Henry; Brianan McGovern; Paul Barham; Fergal C Kelleher; Jean Murphy; Susan Kennedy; Niall Swan; Michael Moriarty; Martin Clynes; Annemarie Larkin
Journal:  Br J Cancer       Date:  2017-09-07       Impact factor: 7.640

6.  Accelerating target deconvolution for therapeutic antibody candidates using highly parallelized genome editing.

Authors:  Jenny Mattsson; Ludvig Ekdahl; Fredrik Junghus; Ram Ajore; Eva Erlandsson; Abhishek Niroula; Maroulio Pertesi; Björn Frendéus; Ingrid Teige; Björn Nilsson
Journal:  Nat Commun       Date:  2021-02-24       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.